tegafur has been researched along with Hepatitis C in 3 studies
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment." | 7.79 | Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013) |
| "We report a case of complete remission of multiple hepatocellular carcinomas after oral administration of enteric-coated tegafur/uracil." | 7.70 | Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. ( Asakura, H; Ebe, Y; Ichida, T; Ishikawa, T; Ishimoto, Y; Naito, M; Nomoto, M; Usuda, H; Yokoyama, J, 1999) |
| "Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment." | 3.79 | Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013) |
| "We report a case of complete remission of multiple hepatocellular carcinomas after oral administration of enteric-coated tegafur/uracil." | 3.70 | Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. ( Asakura, H; Ebe, Y; Ichida, T; Ishikawa, T; Ishimoto, Y; Naito, M; Nomoto, M; Usuda, H; Yokoyama, J, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fushiya, N | 1 |
| Takagi, I | 1 |
| Nishino, H | 1 |
| Akizuki, S | 1 |
| Ohnishi, A | 1 |
| Yamashita, T | 2 |
| Arai, K | 1 |
| Terashima, T | 1 |
| Sunagozaka, H | 1 |
| Shimakami, T | 1 |
| Mizukoshi, E | 1 |
| Sakai, A | 1 |
| Honda, M | 1 |
| Kaneko, S | 1 |
| Ishikawa, T | 1 |
| Ichida, T | 1 |
| Ishimoto, Y | 1 |
| Yokoyama, J | 1 |
| Nomoto, M | 1 |
| Ebe, Y | 1 |
| Usuda, H | 1 |
| Naito, M | 1 |
| Asakura, H | 1 |
3 other studies available for tegafur and Hepatitis C
| Article | Year |
|---|---|
Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; C | 2013 |
[A case report of S-1 monotherapy for advanced hepatocellular carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Combinations; Fatal Outcome; | 2012 |
Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 1999 |